Dr. Jeffrey Weber on Ipilimumab for Melanoma

Jeffrey S. Weber, MD, PhD
Published: Monday, Feb 02, 2015



Jeffrey Weber, MD, PhD, a senior member at the Moffitt Cancer Center, discusses the EORTC 18701 study, which compared ipilimumab with placebo for patients with stage III node-positive melanoma.
The data were impressive, says Weber. The study showed that there was a clear benefit in terms of relapse-free survival (RFS) for the patients on the ipilimumab arm.
The median follow-up was 2.7 years, and RFS rates were 46.5% with ipilimumab versus 34.8% with placebo. The median RFS was 26.1 for ipilimumab versus 17.1 months for placebo.


Jeffrey Weber, MD, PhD, a senior member at the Moffitt Cancer Center, discusses the EORTC 18701 study, which compared ipilimumab with placebo for patients with stage III node-positive melanoma.
The data were impressive, says Weber. The study showed that there was a clear benefit in terms of relapse-free survival (RFS) for the patients on the ipilimumab arm.
The median follow-up was 2.7 years, and RFS rates were 46.5% with ipilimumab versus 34.8% with placebo. The median RFS was 26.1 for ipilimumab versus 17.1 months for placebo.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x